Artificial Intelligence (AI) is rapidly transforming oncology, marking it as the fastest-adopted technology in healthcare. While opinions among oncologists are mixed—roughly one-third believe AI enhances diagnostics, another third disagree—patient skepticism remains over concerns like depersonalization and privacy. Despite uncertainties, investment in AI-centric biotech is booming, with significant funding directed towards AI for drug discovery and digital health tools. Innovative tools, such as ASCO’s AI-powered guidelines assistant and OpenEvidence for research, are aiding in real-time clinical decision-making. AI applications in imaging and pathology demonstrate improved diagnostic accuracy and efficiency. AI is also streamlining clinical trial recruitment, saving time and optimizing patient matching, which enhances access to new treatments. Moreover, patient-facing AI platforms help individuals navigate their healthcare options, leveraging real-time guidelines. As regulatory bodies recognize AI’s role in drug development and clinical trials, its integration in oncology practice is becoming indispensable, signalling a significant shift in healthcare.
Source link
Share
Read more